Nothing Special   »   [go: up one dir, main page]

EP1957514A1 - Promedicaments de substances er-beta-selectives, procedes de realisation associes et compositions pharmaceutiques contenant ces composes - Google Patents

Promedicaments de substances er-beta-selectives, procedes de realisation associes et compositions pharmaceutiques contenant ces composes

Info

Publication number
EP1957514A1
EP1957514A1 EP06829356A EP06829356A EP1957514A1 EP 1957514 A1 EP1957514 A1 EP 1957514A1 EP 06829356 A EP06829356 A EP 06829356A EP 06829356 A EP06829356 A EP 06829356A EP 1957514 A1 EP1957514 A1 EP 1957514A1
Authority
EP
European Patent Office
Prior art keywords
estra
sulfamoylbenzoate
group
trien
vinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06829356A
Other languages
German (de)
English (en)
Inventor
Olaf Peters
Gudrun Reddersen
Ralf Wyrwa
Alexander Hillisch
Walter Elger
Katja Prelle
Peter Droescher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of EP1957514A1 publication Critical patent/EP1957514A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • Prodrugs of ER ⁇ -selective substances processes for their preparation and pharmaceutical compositions containing them
  • the invention relates to prodrugs of ER ⁇ -selective substances of the general formula (I),
  • Estrogens play an important role in the organism in both sexes. Estrogens are involved in the maturation of sex characteristics in the maturing organism. Estrogens in both sexes control the organism's transitions during puberty, such as the growth spurt and then the cessation of bone growth. In all stages of life, estrogens play a central role in bone metabolism in both sexes (1, 4). Their loss leads to the breakdown of bone substance and carries the risk of increased brittleness of the bone.
  • estrogens are predominantly "peripheral" through the aromatization of testosterone or adrenal androgens in various organs of success, such as the CNS, bone, or intestinal epithelium, allowing for physiological estrogen effects in men at very low levels of estradiol in the blood with a genetic defect of the aromatase or the estrogen receptor, the bone is severely disrupted in growth and maintenance (2).
  • WO 01/77139 describes novel 8 ⁇ -substituted estratrienes wherein the 8 ⁇ -substituent is a straight- or branched-chain, optionally partially or fully halogenated alkyl or alkenyl radical having up to 5 carbon atoms, an ethynyl or prop-1-ynyl radical may show, as pharmaceutical active ingredients, a higher in vitro affinity for estrogen receptor preparations of rat prostate than rat uterine estrogen receptor preparations and in vivo a preferential effect on bone compared to uterus and / or pronounced effect on stimulation of expression of 5HT2a receptor and Transporter exhibit. These compounds may preferably be used for the treatment of diseases caused by estrogen deficiency.
  • WO 01/91797 discloses steroidal compounds which are bound to erythrocytes via a group - SO 2 NR 1 R 2 and accumulate there.
  • concentration ratio of the compounds between erythrocytes and plasma is 10- 1000: 1, preferably 30-1000: 1, so that one can speak of a deposit formation in the erythrocytes. Strong binding of the compounds to the erythrocytes avoids metabolism during liver passage. Disadvantageously, despite a reduced metabolization with the indicated dosages no therapeutically relevant drug levels are given.
  • This object is achieved by sulfamoyl compounds of 8 ⁇ -substituted estratrenes of the general formula (I) in which the Z group is bound to the steroid to be released
  • Aryl group, one or R 20 can furthermore denote a hydrogen or R 3 denotes a radical -SO 2 NH 2 or -NHSO 2 NH 2 , where R 1 , R 2 and X, X 1 independently of one another for a hydrogen atom, a
  • Halogen atom, a nitrile group, a nitro group, a Ci. 5- alkyl group, a C p F 2p + 1 group with p 1-3, a group OC (O) -R 20 , COOR 20 , OR 20 , C (O) NHR 20 or OC (O) NH-R 21 stands, wherein R 20 and R 21 is a ds-alkyl group, a C 3 . 8 -cycloalkyl group, an aryl group, a d- 4 -Alkylenaryl distr, a are group or Ca- ⁇ -cycloalkylene-d ⁇ alkyl group and R 20 can also be a hydrogen, and
  • STEROID for a steroidal ABCD ring system of the formula (A) is:
  • R 17 is an OH group, a tri (C 1 -C 4 -alkyl) silyloxy group or a group OC (O) -R 20 or
  • R 8 is a branched or straight-chain, optionally partially or completely halogenated alkyl, alkenyl or alkynyl radical having up to 3 carbon atoms
  • R 16 is a hydrogen, a halogen atom or a methyl group
  • the present invention comprises the new compounds as pharmaceutical active ingredients, their preparation, their therapeutic application and pharmaceutical dosage forms containing the new substances.
  • the invention relates to estrogen derivatives which themselves can not bind to the estrogen receptor and from which the parent compound contained in the body is released, processes for their preparation and pharmaceutical compositions containing these compounds.
  • the compounds according to the invention are prodrugs which, after saponification of the ester group Z, release an ER ⁇ -selective estrogen (parent estrogen).
  • the compounds of the invention have therapeutically favorable estrogenic activities, as far as they are mediated via the ER ß, especially in the central nervous system, in the circulatory system and in the bone.
  • the substances according to the invention are preferably used for oral therapy.
  • the compounds according to the invention have a markedly increased oral bioavailability compared to their parent estrogens, an increased systemic, but generally reduced hepatic estrogenicity. This dissociation of desired and undesired hormonal effects simultaneously enables therapeutically more effective and more compatible drugs compared to the prior art.
  • the substances according to the invention are cleaved enzymatically or hydrolytically in the body, with no steroid sulphatases (STS) being required, for example for the cleavage of estradiol-3-sulphamate.
  • STS steroid sulphatases
  • estradiol estradiol valerate, estrone sulfate, conjugated estrogens
  • high levels of estrone are dominant in the blood (10).
  • blood levels of estradiol are lower than those of estrone. This is disadvantageous because estrone is a less effective estrogen than estradiol.
  • An advantage of the substances according to the invention in comparison with those in the prior art is the preferential release of the respective parent estrogen, thus for example 8 ⁇ -ethylestradiol, 8 ⁇ -methylestradiol, 8 ⁇ -vinylestradiol and 8 ⁇ -difluorovinylestradiol instead of the inactive estrone derivatives.
  • the compounds of the general formula (I) according to the invention or their pharmaceutically acceptable salts can be used as a single component in pharmaceutical preparations or in combination, in particular, with antiestrogens or gestagens. Particularly preferred is the combination with ER ⁇ -selective antiestrogens or with antiestrogens which are peripherally selectively effective, ie, which do not cross the blood-brain barrier.
  • the substances and the pharmaceuticals containing them are particularly suitable for the treatment of peri- and post-menopausal symptoms, in particular hot flashes, insomnia, irritability, mood swings, incontinence, vaginal atrophy, hormone-deficiency-related mood disorders.
  • the substances for hormone substitution and the therapy of hormone-deficiency-related symptoms in surgical, drug or other conditional ovarian dysfunction are suitable. It also includes prevention of bone loss in postmenopausal women and in andropausal men, in hysterectomized women or in women treated with LHRH antagonists or agonists.
  • the prodrugs of the ER ⁇ -selective agonists according to the invention can be used alone or in combination with antiestrogens, aromatase inhibitors or Selective Estrogen Receptor Modulators (SERM) for the treatment of prostatic hyperplasia in order to avoid estrogen deprivation or to reduce their effects.
  • antiestrogens aromatase inhibitors
  • SERM Selective Estrogen Receptor Modulators
  • the antiestrogen used is preferably 7alpha- [9 - [(4, 4,5,5, 5-pentafluoropentyl) sulfinyl] nonyl] estra-1,3,5 (10) -thene-3,17 ⁇ -diol (fulvestrant).
  • aromatase inhibitors to be used, the following are contemplated: anastrozole, atamestane, fadrozole, formestan, letrozole.
  • Suitable SERMs are compounds selected from the following group: raloxifene, tamoxifen, 5- (4- ⁇ 5 - [(RS) - (4,4,5,5,5-pentafluoropentyl) sulfinyl] pentyl ⁇ phenyl) -6 - phenyl-8,9-dihydro-7H-benzocyclohepten-2-ol (WO 00/03979).
  • the compounds are also useful for alleviating the symptoms of andropause and menopause, ie male and female hormone replacement therapy (HRT), both Prophylaxis and treatment, continue to treat the symptoms associated with dysmenorrhea and for the treatment of acne suitable.
  • HRT hormone replacement therapy
  • the substances can also be used for the prophylaxis of hormone-deficiency-induced bone loss and osteoporosis, for the prevention of cardiovascular diseases, in particular vascular diseases such as atherosclerosis, for the inhibition of the proliferation of arterial smooth muscle cells, for the treatment of primary pulmonary hypertension.
  • the substances for the treatment of inflammatory and immune system disorders in particular autoimmune diseases such.
  • autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, Crohn's disease and endometriosis can be used.
  • the compounds can be used in particular for therapies that lead to estrogen deprivation, for example, after treatment with aromatase inhibitors or GnRH antagonists or agonists, for the treatment of arthritic symptoms.
  • the compounds may find use in the treatment of male fertility disorders and prostatic diseases.
  • the compounds according to the invention are suitable for estrogen treatment of prostate carcinoma.
  • the compounds may also be used in combination with the natural vitamin D3 or with calcite analogs for bone formation or as supportive therapy for therapies that cause bone mass loss (for example, therapy with glucocorticoids, aromatase inhibitors, GnRH agonists or antagonists, chemotherapy) ,
  • the compounds of general formula (I) may be used in conjunction with progesterone receptor modulators, for example mesoprogestins such as asoprisnil, in particular for use in hormone replacement therapy and for the treatment of gynecological disorders.
  • progesterone receptor modulators for example mesoprogestins such as asoprisnil, in particular for use in hormone replacement therapy and for the treatment of gynecological disorders.
  • the compounds according to the general formula (I) according to the invention can also be used for the treatment of alopecia caused, for example, by chemotherapy.
  • a therapeutic product containing an estrogen and a pure antiestrogen for simultaneous, sequential or separate use for the selective estrogen therapy of peri- or postmenopausal states has already been described in EP-A 0 346 014.
  • ds-alkyl group is understood to mean a branched or straight-chain alkyl radical having up to 5 carbon atoms which may be substituted, for example, by halogens, OH, CN, for example methyl, ethyl, n-propyl, Propyl, n-butyl, i-butyl, tert-butyl or n-pentyl called.
  • C 3 . 8 -Cycloalkyl a mono- or bicyclic group which may be substituted for example by halogens such as fluorine, chlorine or bromine, OH, CN, such as a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or hydroxycyclohexyl.
  • aryl group is understood as meaning a substituted or unsubstituted aryl radical having 6 to 15 carbon atoms, for example a phenyl group, a substituted phenyl group, such as a halophenyl group or a nitrophenyl group, or a naphthyl group.
  • C 1-4 -alkylene-aryl group is understood to mean a disubstituted alkyl radical which is substituted by at least one aryl radical. Both radicals together have 7 to 15 carbon atoms, where the aryl radical may carry further substituents, for example a halogen atom Examples are a benzyl group or a halobenzyl group.
  • C ⁇ alkylene-Ca- ⁇ -cycloalkyl group is a disubstituted alkyl radical Both residues is in the sense of the present application understood to be cycloalkyl with a C 3. 8 is substituted. Together have 4 to 12 carbon atoms, whereby the Cycloalkyl may carry further substituents such as, for example, a halogen atom, examples being a cyclopentylethyl, cyclohexylmethyl or cyclohexylethyl group.
  • a trialkylsilyloxy group is, for example, a trimethylsilyloxy. or tert-butyldimethylsilyloxy group.
  • halogen atom is understood to mean a fluorine, chlorine, bromine or iodine atom, preference being given to fluorine, chlorine and bromine.
  • the number "n” is preferably 0.1 or 2.
  • R 1 is preferably a group -SO 2 NH 2 , wherein R 2 , R 3 , X 1 and X are independently of one another preferably an H, F, Cl atom, an OH or a methoxy group.
  • R 2 is preferably a group -SO 2 NH 2 , wherein R 1 , R 3 , X 1 and X are independently of one another preferably an H, F, Cl atom, an OH or a methoxy group.
  • R 3 is preferably a group -SO 2 NH 2 , wherein R 1 , R 2 , X 1 and X are independently of one another preferably an H, F, Cl atom, an OH or a methoxy group.
  • X 1 is preferably an H atom.
  • R 8 is preferably methyl, ethyl, vinyl, difluorovinyl, ethynyl or prop-1-ynyl.
  • R 8 are methyl, ethyl, vinyl or difluorovinyl.
  • Y is preferably OH, OMe, a trimethylsilyloxy, tert-butyldimethylsilyloxy, a benzoate, a sulphamoylbenzoate, acetate, propionate, valerate, butcyclate or cyclopentylpropionate radical.
  • R 17 is preferably an OH, a trimethylsilyloxy, an acetate, propionate, valerate, a benzoate, an optionally halogenated Sulfamoylbenzoat- radical.
  • Particularly preferred compounds according to the invention are listed below: 1) (3'-hydroxy-8'-methyl-estra-1 ', 3', 5 '(10') -trien-17'- ⁇ -yl) 3 sulfamoyl benzoate, 2) (3'-hydroxy-8'-ethyl-estra-1 ⁇ 3 ', 5' (10 ') -trien-17'- ⁇ -yl) 3-sulfamoylbenzoate,
  • the SO 2 -NH 2 group of the substances according to the invention can lead to an accumulation in erythrocytes by binding to carbonic anhydrases.
  • the displacement of estradiol-3-sulfamate from the erythrocyte binding by test substances is measured.
  • Experimental approach Human blood is treated with a mixture of 14 C-labeled and unlabeled estradiol sulfamate. At the selected operating point, the erythrocytes are saturated and the distribution in plasma / erythrocytes is 40:60.
  • a second blood sample is spiked with a mixture of 14 C-labeled estradiol sulfamate and unlabeled test substance.
  • the concentration ratios of the compounds according to the invention between erythrocytes and plasma are not in a range of 10-1000: 1, but in the range ⁇ 10: 1.
  • the ratio is, for example, 1, 4: 1.
  • Carbonic anhydrases catalyze the CO 2 hydrogenation.
  • the present invention therefore also relates to pharmaceutical compositions containing at least one compound of general formula (I), optionally together with pharmaceutically acceptable excipients and carriers.
  • the substances according to the invention have pharmacodynamically and pharmacokinetically improved properties relative to their parent estrogens, which are based on a reduced hepatic extraction and more uniform and longer-lasting blood levels of the released estrogen.
  • the Er ⁇ -selective compounds of general formula (I) are administered orally.
  • gynecological disorders such as ovarian dysfunction and endometriosis dosages between 0.5 and 100 mg come for the treatment of male and female fertility disorders 5 micrograms to 50 mg for hormone-related tumors 5 to 500 mg and male or female hormone replacement therapy 5 micrograms 100 mg into consideration.
  • compositions contain, in addition to customary carriers and / or diluents, at least one compound of the general formula I.
  • the substances according to the invention can also be used therapeutically in combination with a gestagen, antigestagen or mesoprogestin.
  • the substances according to the invention are preferably used individually as active ingredient in pharmaceutical preparations.
  • compositions of the invention are mixed with the usual solid or liquid excipients or diluents and the commonly used pharmaceutical excipients according to the desired mode of administration with a suitable dosage produced in a known manner.
  • the preferred formulations consist of a dosage form which is suitable for oral administration.
  • dosage forms are, for example, tablets, coated tablets, dragees, capsules, pills, powders, solutions or suspensions or depot forms.
  • Corresponding tablets for example, by mixing the active ingredient with known excipients, for example inert diluents such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc and / or agents to achieve Depot effect such as carboxyl polymethylene, carboxymethyl cellulose, cellulose acetate phthalate or polyvinyl acetate, are obtained.
  • excipients for example inert diluents such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc and / or agents to achieve Depot effect such as carboxyl polymethylene, carb
  • Coated tablets can accordingly be prepared by coating cores produced analogously to the tablets with agents customarily used in tablet coatings, for example polyvinylpyrrolidone or shellac, gum arabic, talc, titanium oxide or sugar.
  • the dragee wrapper can also consist of several layers, wherein the auxiliaries mentioned above in the case of the tablets can be used.
  • Solutions or suspensions with the compounds of general formula I according to the invention may additionally taste-improving agents such as saccharin, cyclamate or sugar and z.
  • B. flavorings such as vanillin or orange extract. They may also contain suspending aids such as sodium carboxymethylcellulose or preservatives such as p-hydroxybenzoates.
  • the capsules containing the compounds of the general formula I can be prepared, for example, by mixing the compound (s) of the general formula I with an inert carrier such as lactose or sorbitol and encapsulating it in gelatine capsules.
  • an inert carrier such as lactose or sorbitol
  • Suitable suppositories can be prepared, for example, by mixing with suitable carriers such as neutral fats or polyethylene glycol or derivatives thereof.
  • Example 1 (3'-hydroxy-8-vinylestra-1 S3S5 '(10-trien-17'- ⁇ -yl) -3-sulfamoylbenzoate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des promédicaments d'estratriènes à substitution 8β de formule (I), dans lesquels le groupe Z est lié au stéroïde, (I). La présente invention porte également sur des procédés pour les réaliser, sur des compositions pharmaceutiques contenant ces composés et sur leur utilisation. Les composés de l'invention de formule (I) ne se lient pas au récepteur d'oestrogène alpha et/ou bêta, mais ils se lient à des carboanhydrases et inhibent ces enzymes.
EP06829356A 2005-11-29 2006-11-27 Promedicaments de substances er-beta-selectives, procedes de realisation associes et compositions pharmaceutiques contenant ces composes Withdrawn EP1957514A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005057225A DE102005057225A1 (de) 2005-11-29 2005-11-29 Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
PCT/EP2006/011728 WO2007062876A1 (fr) 2005-11-29 2006-11-27 Promedicaments de substances er-beta-selectives, procedes de realisation associes et compositions pharmaceutiques contenant ces composes

Publications (1)

Publication Number Publication Date
EP1957514A1 true EP1957514A1 (fr) 2008-08-20

Family

ID=37909446

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06829356A Withdrawn EP1957514A1 (fr) 2005-11-29 2006-11-27 Promedicaments de substances er-beta-selectives, procedes de realisation associes et compositions pharmaceutiques contenant ces composes

Country Status (14)

Country Link
EP (1) EP1957514A1 (fr)
JP (1) JP2009517426A (fr)
KR (1) KR20080072087A (fr)
CN (1) CN101316856A (fr)
AU (1) AU2006319382A1 (fr)
BR (1) BRPI0619237A2 (fr)
CA (1) CA2630438A1 (fr)
CR (1) CR9997A (fr)
DE (1) DE102005057225A1 (fr)
EA (1) EA200801272A1 (fr)
EC (1) ECSP088482A (fr)
NO (1) NO20082918L (fr)
WO (1) WO2007062876A1 (fr)
ZA (1) ZA200805658B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105960236A (zh) 2013-12-05 2016-09-21 卡罗医药股份公司 用于治疗间皮瘤的雌激素受体β激动剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2245694T3 (es) * 2000-04-12 2006-01-16 Schering Aktiengesellschaft Derivados de 11beta-pentil- y 11beta-hexil-estra-1,3,5(10)-trienos sustituidos en la posicion 8beta.
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE102004025966A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
US7534780B2 (en) * 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007062876A1 *

Also Published As

Publication number Publication date
DE102005057225A1 (de) 2007-05-31
EA200801272A1 (ru) 2008-10-30
CR9997A (fr) 2008-09-22
ECSP088482A (es) 2008-06-30
BRPI0619237A2 (pt) 2011-09-20
CA2630438A1 (fr) 2007-06-07
AU2006319382A1 (en) 2007-06-07
KR20080072087A (ko) 2008-08-05
CN101316856A (zh) 2008-12-03
ZA200805658B (en) 2010-01-27
NO20082918L (no) 2008-06-27
WO2007062876A1 (fr) 2007-06-07
JP2009517426A (ja) 2009-04-30

Similar Documents

Publication Publication Date Title
EP2456781B1 (fr) Dérivés 17-hydroxy-17-pentafluoroéthyl-estra-4,9(10)-diène-11-acyloxyalcénylphényle, procédés de préparation et utilisation pour le traitement de maladies
EP2432798B1 (fr) Dérivé 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés, son procédé de production et sa utilisation pour le traitement de maladies
EP1272504B1 (fr) Estratrienes a substitution 8beta-hydrocarbyle utilises comme oestrogenes a action selective
DE60025817T2 (de) Ent-steroide als selektiv wirksame estrogene
US20070197488A1 (en) Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
EP0775155A1 (fr) Derives estra-1,3,5(10)-triene, leurs procedes de preparation et compositions pharmaceutiques les contenant
EP1525215B1 (fr) Modulateurs de recepteurs de progesterone presentant une activite antigonadotrope augmentee, destines au controle de fertilite et au traitement hormonal substitutif chez la femme
DE10236405A1 (de) Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US20070123500A1 (en) Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
KR19980071540A (ko) 피임 및 항-골다공증 활성을 갖는 스테로이드 화합물
EP1226155B1 (fr) 18-nor-steroides utilises comme oestrogenes a effet selectif
EP1747230A1 (fr) Phenylesters substitues par aminosulfonyle ou aminosulfonylamino comme promedicaments a base d'oestradiol
WO2005113575A1 (fr) Promedicaments steroides a effet androgene
EP1747231A1 (fr) Phenylester substitue par aminosulfonyle ou aminosulfonylamino comme promedicaments a base d'oestriol et d'oestetrol
WO2007062877A2 (fr) PROMEDICAMENTS DE SUBSTANCES ERβ-SELECTIVES, PROCEDES DE REALISATION ASSOCIES ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSES
EP1957514A1 (fr) Promedicaments de substances er-beta-selectives, procedes de realisation associes et compositions pharmaceutiques contenant ces composes
EP1737880B1 (fr) 17alpha-fluoro-17beta-hydroximinomethyl-steroides, leur procede de production, et compositions pharmaceutiques les contenant
DE3644358A1 (de) 10(beta)-alkynyl-4,9(11)-oestradien-derivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten
MX2008006856A (en) Prodrug erî²-selective substances, methods for the production thereof and pharmaceutical compositions containing said compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080630

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ELGER, WALTER

Inventor name: HILLISCH, ALEXANDER

Inventor name: WYRWA, RALF

Inventor name: REDDERSEN, GUDRUN

Inventor name: PETERS, OLAF

Inventor name: DROESCHER, PETER

Inventor name: PRELLE, KATJA

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100715